Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Astellas Pharma Inc.

    OTC: ALPMY · Real-Time Price · USD
    9.64
    -0.15 (-1.53%)
    At close: Jun 13, 2025, 3:59 PM

    Astellas Pharma Statistics

    Share Statistics

    Astellas Pharma has 1.8B shares outstanding. The number of shares has increased by -0.17% in one year.

    Shares Outstanding

    n/a
    		 1.8B

    Shares Change (YoY)

    n/a
    		 -0.17%

    Shares Change (QoQ)

    n/a
    		 0%

    Owned by Institutions (%)

    n/a
    		 n/a

    Shares Floating

    n/a
    		 1.8B

    Failed to Deliver (FTD) Shares

    n/a
    		 1,433

    FTD / Avg. Volume

    n/a
    		 0.79%

    Short Selling Information

    The latest short interest is 62.87K, so 0% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 62.87K

    Short % of Shares Out

    n/a
    		 n/a

    Short % of Float

    n/a
    		 n/a

    Short Ratio (days to cover)

    n/a
    		 1

    Valuation Ratios

    The PE ratio is 171.73 and the forward PE ratio is 0.11. Astellas Pharma's PEG ratio is -2.08.

    PE Ratio

    n/a
    		 171.73

    Forward PE

    n/a
    		 0.11

    PS Ratio

    n/a
    		 1.83

    Forward PS

    n/a
    		 0

    PB Ratio

    n/a
    		 1.83

    P/FCF Ratio

    n/a
    		 32.53

    PEG Ratio

    n/a
    		 -2.08
    Financial Ratio History

    Enterprise Valuation

    Astellas Pharma has an Enterprise Value (EV) of 3,511.5B.

    EV / Sales

    n/a
    		 2.19

    EV / EBITDA

    n/a
    		 18.03

    EV / EBIT

    n/a
    		 20.36

    EV / FCF

    n/a
    		 39.03

    Financial Position

    The company has a current ratio of 0.93, with a Debt / Equity ratio of 0.58.

    Current Ratio

    n/a
    		 0.93

    Quick Ratio

    n/a
    		 0.74

    Debt / Equity

    n/a
    		 0.58

    Debt / EBITDA

    n/a
    		 4.72

    Debt / FCF

    n/a
    		 10.22

    Interest Coverage

    n/a
    		 2.13

    Financial Efficiency

    Return on Equity is 1.07% and Return on Invested Capital is 0.63%.

    Return on Equity

    n/a
    		 1.07%

    Return on Assets

    n/a
    		 0.48%

    Return on Invested Capital

    n/a
    		 0.63%

    Revenue Per Employee

    n/a
    		 $108,694,049.07

    Profits Per Employee

    n/a
    		 $1,155,279.92

    Employee Count

    n/a
    		 14,754

    Asset Turnover

    n/a
    		 0.45

    Inventory Turnover

    n/a
    		 1.18

    Taxes

    Income Tax

    n/a
    		 7.92B

    Effective Tax Rate

    n/a
    		 31.74%

    Stock Price Statistics

    The stock price has increased by 1.88% in the last 52 weeks. The beta is 0.13, so Astellas Pharma's price volatility has been higher than the market average.

    Beta

    n/a
    		 0.13

    52-Week Price Change

    n/a
    		 1.88%

    50-Day Moving Average

    n/a
    		 9.56

    200-Day Moving Average

    n/a
    		 10.34

    Relative Strength Index (RSI)

    n/a
    		 54.58

    Average Volume (20 Days)

    n/a
    		 181,214

    Income Statement

    In the last 12 months, Astellas Pharma had revenue of 1,603.7B and earned 17.05B in profits. Earnings per share was 9.51.

    Revenue

    n/a
    		 1,603.7B

    Gross Profit

    n/a
    		 1,311.2B

    Operating Income

    n/a
    		 25.52B

    Net Income

    n/a
    		 17.05B

    EBITDA

    n/a
    		 194.81B

    EBIT

    n/a
    		 36.97B

    Earnings Per Share (EPS)

    n/a
    		 9.51
    Full Income Statement

    Balance Sheet

    The company has 335.69B in cash and 920.02B in debt, giving a net cash position of -584.33B.

    Cash & Cash Equivalents

    n/a
    		 335.69B

    Total Debt

    n/a
    		 920.02B

    Net Cash

    n/a
    		 -584.33B

    Retained Earnings

    n/a
    		 809.4B

    Total Assets

    n/a
    		 3,735.5B

    Working Capital

    n/a
    		 -133.15B
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was 172.47B and capital expenditures -82.5B, giving a free cash flow of 89.98B.

    Operating Cash Flow

    n/a
    		 172.47B

    Capital Expenditures

    n/a
    		 -82.5B

    Free Cash Flow

    n/a
    		 89.98B

    FCF Per Share

    n/a
    		 50.2
    Full Cash Flow Statement

    Margins

    Gross margin is 81.76%, with operating and profit margins of 1.59% and 1.06%.

    Gross Margin

    n/a
    		 81.76%

    Operating Margin

    n/a
    		 1.59%

    Pretax Margin

    n/a
    		 1.56%

    Profit Margin

    n/a
    		 1.06%

    EBITDA Margin

    n/a
    		 12.15%

    EBIT Margin

    n/a
    		 1.59%

    FCF Margin

    n/a
    		 5.61%

    Dividends & Yields

    ALPMY pays an annual dividend of $0.32, which amounts to a dividend yield of 2.77%.

    Dividend Per Share

    n/a
    		 $0.32

    Dividend Yield

    n/a
    		 2.77%

    Dividend Growth (YoY)

    n/a
    		 -1.09%

    Payout Ratio

    n/a
    		 159.22%

    Earnings Yield

    n/a
    		 0.58%

    FCF Yield

    n/a
    		 3.07%
    Dividend Details

    Analyst Forecast

    Currently there are no analyst rating for ALPMY.

    Price Target

    n/a
    		 n/a

    Price Target Difference

    n/a
    		 n/a

    Analyst Consensus

    n/a
    		 n/a

    Analyst Count

    n/a
    		 n/a
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 $47.55

    Lynch Upside

    n/a
    		 386.69%

    Graham Number

    n/a
    		 436.5

    Graham Upside

    n/a
    		 4367.76%

    Stock Splits

    The last stock split was on Apr 2, 2014. It was a forward split with a ratio of 5:4.

    Last Split Date

    n/a
    		 Apr 2, 2014

    Split Type

    n/a
    		 forward

    Split Ratio

    n/a
    		 5:4

    Scores

    Altman Z-Score

    n/a
    		 0.74

    Piotroski F-Score

    n/a
    		 5

    Add to Watchlist